Citations

Clear

3942 citation(s) found for "To, Van".

Optimizing Quality of Life and Minimizing Morbidity through Nasal Preservation in Endoscopic Skull Base Surgery: A Contemporary Review
Rowan, Nicholas R. , Celda, María Peris, Mukherjee, Debraj , Gompel, Jamie J. Van , Pinheiro-Neto, Carlos, Rowan, Nicholas R , Mukherjee, Debraj , Van Gompel, Jamie J , Choby, Garret , Pinheiro‐Neto, Carlos , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | August 9, 2022 | Volume: 83 | Issue: 06 | Pages: 602-610

10.1055/s-0042-1749654 | PMID 36393878 Get It

Abstract Introduction Endoscopic endonasal approaches (EEAs) are increasingly utilized for intracranial pathology. As opposed to sinonasal tumors, the nasal cavity is being used as a corridor to access these intracranial tumors but is not the site of primary surgical intent. Accordingly, there has been recent interest in preserving intranasal structures not directly involved by tumor and improving postoperative sinonasal quality of life (QOL). Objectives The aim of the study is to highlight recent advances in EEA techniques focused on improving sinonasal QOL including turbinate preservation, reducing the morbidity of reconstructive techniques, and the development of alternative minimally invasive EEA corridors. Methods The method of the study involves contemporary literature review and summary of implications for clinical practice. Results Nasoseptal flap (NSF) harvest is associated with significant morbidity including septal perforation, prolonged nasal crusting, and external nasal deformities. Various grafting and local rotational flaps have demonstrated the ability to significantly limit donor site morbidity. Free mucosal grafts have re-emerged as a reliable reconstructive option for sellar defects with an excellent sinonasal morbidity profile. Middle turbinate preservation is achievable in most EEA cases and has not been shown to cause postoperative obstructive sinusitis. Recently developed minimally invasive EEA techniques such as the superior ethmoidal approach have been described to better preserve intranasal structures while allowing intracranial access to resect skull base tumors and have shown promising sinonasal QOL results. Conclusion This contemporary review discusses balancing effective skull base reconstructive techniques with associated morbidity, the role of turbinate preservation in EEA, and the development of unique EEA techniques that allow for increased nasal structure preservation.
Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
Bravi, Carlo Andrea , Heidenreich, Axel , Gandaglia, Giorgio , Cucchiara, Vito , Osmonov, Daniar , Juenemann, Klaus‐Peter, Karnes, R. Jeffrey , Kretschmer, Alexander , Büchner, Alexander , Hiester, Andreas , Albers, Peter , Joniau, Steven , Shariat, Shahrokh F., Graefen, Markus , Karakiewicz, Pierre I. , Montorsi, Francesco , Briganti, Alberto , Pfister, David, Larcher, Alessandro , Bravi, Carlo A , Gandaglia, Giorgio , Mazzone, Elio , Karnes, Jeffrey , Kretschmer, Alexander , Devos, Gaëtan , Montorsi, Francesco , Pfister, David , Joniau, Steven , Fossati, Nicola , Suardi, Nazareno , Stabile, Armando , Stief, Christian G. , Poppel, Hendrik Van , Grubmüller, Bernhard , Tilki, Derya , Gill, Inderbir S. , Mottrie, Alexandre

Mayo Clinic

BJUI Compass | August 5, 2022 | Volume: 4 | Issue: 1 | Pages: 123-129

10.1002/bco2.182 | PMID 36569505 Get It

AbstractObjectiveTo evaluate the relationship between pre‐operative PSA value, 68Ga‐prostate‐specific‐membrane‐antigen (PSMA) PET performance and oncologic outcomes after salvage lymph node dissection (sLND) for biochemical recurrent prostate cancer (PCa).Patients and methodsThe study included 164 patients diagnosed with ≤2 pelvic lymph‐node recurrence(s) of PCa documented on 68Ga‐PSMA PET scan and treated with pelvic ± retroperitoneal sLND at 11 high‐volume centres between 2012 and 2019. Pathologic findings were correlated to PSA values at time of sLND, categorized in early (<0.5 ng/ml), low (0.5–0.99 ng/ml), moderate (1–1.5 ng/ml) and high (>1.5 ng/ml). Clinical recurrence (CR)‐free survival after sLND was calculated using multivariable analyses and plotted over pre‐operative PSA value.ResultsMedian [interquartile range (IQR)] PSA at sLND was 1.1 (0.6, 2.0) ng/ml, and 131 (80%) patients had one positive spot at PET scan. All patients received pelvic sLND, whereas 91 (55%) men received also retroperitoneal dissection. Median (IQR) number of node removed was 15 (6, 28). The rate of positive pathology increased as a function of pre‐operative PSA value, with highest rates for patients with pre‐operative PSA > 1.5 ng/ml (pelvic‐only sLNDs: 84%; pelvic + retroperitoneal sLNDs: 90%). After sLND, PSA ≤ 0.3 ng/ml was detected in 67 (41%) men. On multivariable analyses, pre‐operative PSA was associated with PSA response (p < 0.0001). There were 51 CRs after sLND. After adjusting for confounders, we found a significant, non‐linear relationship between PSA level at sLND and the 12‐month CR‐free survival (p < 0.0001), with the highest probability of freedom from CR for patients who received sLND at PSA level ≥1 ng/ml.ConclusionsIn case of PET‐detected nodal recurrences amenable to sLND, salvage surgery was associated with the highest short‐term oncologic outcomes when performed in men with PSA ≥ 1 ng/ml. Awaiting confirmatory data from prospective trials, these findings may help physicians to optimize the timing for 68Ga‐PSMA PET in biochemical recurrent PCa.
Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis
Siddiqi, Tariq Jamal , Ahmed, Aymen , Greene, Stephen J. , Oshunbade, Adebamike , Hall, Michael E. , Jain, Vardhmaan , Khan, Muhammad Shahzeb , Murad, Mohammad Hassan, Shahid, Izza , Usman, Muhammad , Alkhouli, Mohamad , Murad, M. Hassan , Khera, Rohan , Spall, Harriette G.C. Van

Mayo Clinic

European Journal of Preventive Cardiology | August 3, 2022 | Volume: 29 | Issue: 15 | Pages: 2027-2048

10.1093/eurjpc/zwac148 | PMID 35919956 Get It

Abstract Aims There are several risk scores designed to predict mortality in patients with heart failure (HF). This study aimed to assess performance of risk scores validated for mortality prediction in patients with acute HF (AHF) and chronic HF. Methods and results MEDLINE and Scopus were searched from January 2015 to January 2021 for studies which internally or externally validated risk models for predicting all-cause mortality in patients with AHF and chronic HF. Discrimination data were analysed using C-statistics, and pooled using generic inverse-variance random-effects model. Nineteen studies (n = 494 156 patients; AHF: 24 762; chronic HF mid-term mortality: 62 000; chronic HF long-term mortality: 452 097) and 11 risk scores were included. Overall, discrimination of risk scores was good across the three subgroups: AHF mortality [C-statistic: 0.76 (0.68–0.83)], chronic HF mid-term mortality [1 year; C-statistic: 0.74 (0.68–0.79)], and chronic HF long-term mortality [≥2 years; C-statistic: 0.71 (0.69–0.73)]. MEESSI-AHF [C-statistic: 0.81 (0.80–0.83)] and MARKER-HF [C-statistic: 0.85 (0.80–0.89)] had an excellent discrimination for AHF and chronic HF mid-term mortality, respectively, whereas MECKI had good discrimination [C-statistic: 0.78 (0.73–0.83)] for chronic HF long-term mortality relative to other models. Overall, risk scores predicting short-term mortality in patients with AHF did not have evidence of poor calibration (Hosmer–Lemeshow P &gt; 0.05). However, risk models predicting mid-term and long-term mortality in patients with chronic HF varied in calibration performance. Conclusions The majority of recently validated risk scores showed good discrimination for mortality in patients with HF. MEESSI-AHF demonstrated excellent discrimination in patients with AHF, and MARKER-HF and MECKI displayed an excellent discrimination in patients with chronic HF. However, modest reporting of calibration and lack of head-to-head comparisons in same populations warrant future studies.
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
Midgette, Bria, Strunk, Andrew , Akilov, Oleg E. , Ardon, Christine B. , Cohen, Arnon D. , Cohen, Steven A. , Daveluy, Steven , Delage, M. , Esmann, Solveig, Fisher, Shani , Głowaczewska, Amelia , Brant, Elena Gonzalez, Guilbault, Sandra , Hughes, Rosalind , Ingram, John R , Jemec, Gregor B. E. , Ju, Qiang , Kappe, Naomi , Kirby, Joslyn S. , Matusiak, Łukasz , Micha, Stella, Miller, Angela P., Moseng, Dagfinn, Naik, Haley B. , Nassif, Aude , Nikolakis, Georgios , Pascual, J.C. , Resnik, Barry I., Riad, Hassan, Sayed, Christopher J. , Soliman, Yssra , Szepietowski, Jacek C. , Thorlacius, Linnea , Zee, Hessel H. van der , Villumsen, Bente , Wang, Lanqi , Garg, Amit , Cohen, Steven , Daveluy, Steven , Ingram, J R , Jemec, G B E , Micheletti, Robert , Naik, Haley , Paek, So Yeon , Sayed, Christopher , Szepietowski, Jacek C , Wang, Lanqi , Garg, Amit , Thorlacius, L , Akilov, Oleg E , van der Zee, Hessel H , Alavi, Afsáneh , Bechara, Falk G. , Mármol, V. del , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Grimstad, Øystein , Hamzavi, Iltefat H. , Kirby, Brian , Lowes, Michelle A , Paek, So Yeon , Prens, Errol P. , Smith, Saxon D. , Tan, Jerry K.L. , Tzellos, Thrasyvoulos , Zouboulis, Christos C.

Mayo Clinic

British Journal of Dermatology | July 30, 2022 | Volume: 187 | Issue: 6 | Pages: 927-935

10.1111/bjd.21798 | PMID 36056741 Get It

Abstract Background Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. Methods Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients’ self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from ‘very dissatisfied’ to ‘very satisfied’. Results The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62–2·44, P &lt; 0·001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2·36, 95% CI 1·74–3·19, P &lt; 0·001] relative to treatment with nonbiologic systemic medications. Factors associated with lower treatment satisfaction included smoking (OR 0·78, 95% CI 0·62–0·99; active vs. never), depression (OR 0·69, 95% CI 0·54–0·87), increasing number of comorbidities (OR 0·88 per comorbidity, 95% CI 0·81–0·96) and increasing flare frequency. Conclusions There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication. Factors that appear to lower treatment satisfaction include active smoking, depression, accumulation of comorbid conditions and increasing flare frequency. Awareness of these factors may support partnered decision making with the goal of improving treatment outcomes. What is already known about this topic? Nearly half of patients with hidradenitis suppurativa report dissatisfaction with their treatments. What does this study add? Satisfaction with treatment is increased by receiving care from a dermatologist and treatment with biologics.Satisfaction with treatment is decreased by tobacco smoking, accumulation of comorbid conditions including depression, and higher flare frequency. What are the clinical implications of this work? Awareness of the identified factors associated with poor treatment satisfaction may support partnered decision making and improve treatment outcomes.
Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data fromCALGB80405 (Alliance)/SWOG80405
Blarigan, Erin L. Van , Bainter, Tiffany M., Ng, Kimmie , Niedzwiecki, Donna , Giovannucci, Edward L. , Lenz, Heinz‐Josef , Polite, Blasé N. , Höchster, Howard S. , Goldberg, Richard M. , Blanke, Charles D. , Ciombor, Kristen K. , Meyerhardt, Jeffrey A. , Van Blarigan, Erin L , Lenz, Heinz-Josef , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Ma, Chao , Ou, Fang‐Shu , Venook, Alan P. , Mayer, Robert J. , O’Reilly, Eileen M.

Mayo Clinic

International Journal of Cancer | July 29, 2022 | Volume: 152 | Issue: 2 | Pages: 123-136

10.1002/ijc.34230 | PMID 35904874 Get It

AbstractData on diet and survival among people with metastatic colorectal cancer are limited. We examined dietary fat in relation to all‐cause mortality and cancer progression or death among 1149 people in the Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group (SWOG) 80405 trial who completed a food frequency questionnaire at initiation of treatment for advanced or metastatic colorectal cancer. We examined saturated, monounsaturated, total and specific types (n‐3, long‐chain n‐3 and n‐6) of polyunsaturated fat, animal and vegetable fats. We hypothesized higher vegetable fat intake would be associated with lower risk of all‐cause mortality and cancer progression. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI). Over median follow‐up of 6.1 years (interquartile range [IQR]: 5.3, 7.2 y), we observed 974 deaths and 1077 events of progression or death. Participants had a median age of 59 y; 41% were female and 86% identified as White. Moderate or higher vegetable fat was associated with lower risk of mortality and cancer progression or death (HRs comparing second, third and fourth to first quartile for all‐cause mortality: 0.74 [0.62, 0.90]; 0.75 [0.61, 0.91]; 0.79 [0.63, 1.00];Ptrend: .12; for cancer progression or death: 0.74 [0.62, 0.89]; 0.78 [0.64, 0.95]; 0.71 [0.57, 0.88];Ptrend: .01). No other fat type was associated with all‐cause mortality and cancer progression or death. Moderate or higher vegetable fat intake may be associated with lower risk of cancer progression or death among people with metastatic colorectal cancer.
Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient With Meningoencephalitis
Al-Heeti, Omar, Wu, En‐Ling , Saluja, Rasleen K, Ramsey, Glenn , Matkovic, Eduard , Banach, Bridget S. , Wilson, Michael R. , Miller, Steve , McCabe, Muniba, Bari, Chowdhury, Zimler, Rebecca , Freeman, Debbie, Popovitch, Jonathan M., Annambhotla, Pallavi , Lehman, Jennifer , Fitzpatrick, Kelly A., Velez, Jason O. , Davis, Emily H. , Hughes, Holly R. , Panella, Amanda J., Staples, J. Erin , Gould, Carolyn V. , Wilson, Michael R , Ison, Michael G. , Saluja, Rasleen K, Ha, Kevin, Hall, Scott, Chiu, Charles Y. , Babiker, Hani M. , Freeman, Debbie, Popovitch, Jonathan, Brault, Aaron C. , van Duin, David

Mayo Clinic

Clinical Infectious Diseases | July 27, 2022 | Volume: 76 | Issue: 3 | Pages: e1320-e1327

10.1093/cid/ciac566 | PMID 35883256 Get It

Abstract Background Cache Valley virus (CVV) is a mosquito-borne virus that is a rare cause of disease in humans. In the fall of 2020, a patient developed encephalitis 6 weeks following kidney transplantation and receipt of multiple blood transfusions. Methods After ruling out more common etiologies, metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) was performed. We reviewed the medical histories of the index kidney recipient, organ donor, and recipients of other organs from the same donor and conducted a blood traceback investigation to evaluate blood transfusion as a possible source of infection in the kidney recipient. We tested patient specimens using reverse-transcription polymerase chain reaction (RT-PCR), the plaque reduction neutralization test, cell culture, and whole-genome sequencing. Results CVV was detected in CSF from the index patient by mNGS, and this result was confirmed by RT-PCR, viral culture, and additional whole-genome sequencing. The organ donor and other organ recipients had no evidence of infection with CVV by molecular or serologic testing. Neutralizing antibodies against CVV were detected in serum from a donor of red blood cells received by the index patient immediately prior to transplant. CVV neutralizing antibodies were also detected in serum from a patient who received the co-component plasma from the same blood donation. Conclusions Our investigation demonstrates probable CVV transmission through blood transfusion. Clinicians should consider arboviral infections in unexplained meningoencephalitis after blood transfusion or organ transplantation. The use of mNGS might facilitate detection of rare, unexpected infections, particularly in immunocompromised patients.
The Association between Muscle Quantity and Overall Survival Depends on Muscle Radiodensity: A Cohort Study in Non-Small-Cell Lung Cancer Patients
Amsterdam, Wouter A. C. van , Harlianto, Netanja I. , Verhoeff, Joost J.C. , Moeskops, Pim , Jong, Pim A. de , Leiner, Tim

Mayo Clinic

Journal of Personalized Medicine | July 21, 2022 | Volume: 12 | Issue: 7 | Pages: 1191

10.3390/jpm12071191 | PMID 35887688 Get It

The prognostic value of CT-derived muscle quantity for overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) is uncertain due to conflicting evidence. We hypothesize that increased muscle quantity is associated with better OS in patients with normal muscle radiodensity but not in patients with fatty degeneration of muscle tissue and low muscle radiodensity. We performed an observational cohort study in NSCLC patients treated with radiotherapy. A deep learning algorithm was used to measure muscle quantity as psoas muscle index (PMI) and psoas muscle radiodensity (PMD) on computed tomography. The potential interaction between PMI and PMD for OS was investigated using Cox proportional-hazards regression. Baseline adjustment variables were age, sex, histology, performance score and body mass index. We investigated non-linear effects of continuous variables and imputed missing values using multiple imputation. We included 2840 patients and observed 1975 deaths in 5903 patient years. The average age was 68.9 years (standard deviation 10.4, range 32 to 96) and 1692 patients (59.6%) were male. PMI was more positively associated with OS for higher values of PMD (hazard ratio for interaction 0.915; 95% confidence interval 0.861–0.972; p-value 0.004). We found evidence that high muscle quantity is associated with better OS when muscle radiodensity is higher, in a large cohort of NSCLC patients treated with radiotherapy. Future studies on the association between muscle status and OS should accommodate this interaction in their analysis for more accurate and more generalizable results.
Diagnostic Delay in Human Papillomavirus Negative Oropharyngeal Squamous Cell Carcinoma
Karp, Emily E. , O’Byrne, Thomas J., Lu, Lauren , Routman, David M. , Wittich, Michelle A. Neben, Price, Katharine A. , Tasche, Kendall K. , Moore, Eric J. , Abel, Kathryn M. Van , Yin, Linda X , O'Byrne, Thomas Jamie, Lu, Lauren Y, Routman, David M , Lester, Scott C. , Neben Wittich, Michelle A, Moore, Eric J , Van Abel, Kathryn M , Yin, Linda X. , Daniel, J. , Chintakuntlawar, Ashish V. , Price, Daniel L.

Mayo Clinic

The Laryngoscope | July 19, 2022 | Volume: 133 | Issue: 6 | Pages: 1394-1401

10.1002/lary.30307 | PMID 35851669 Get It

ObjectiveFailure to recognize symptoms of non‐human papillomavirus‐associated oropharyngeal squamous cell carcinoma (HPV(−)OPSCC) at presentation can delay diagnosis and treatment. We aim to identify patient factors and provider practice patterns that delay presentation and care in HPV(−)OPSCC.MethodsRetrospective review at a tertiary care center. Patients with HPV(−)OPSCC receiving treatment from 2006 to 2016. Patients were excluded if their date of symptom onset or diagnosis was unknown after thorough review of the electronic medical record or their tissue was not tested for HPV or p16. Clinical data, workup, and care timelines were abstracted. Univariate and multivariable linear regressions were performed to determine associations between patient and provider factors and delays in care.ResultsOf 70 included patients, 52 (74%) were male and mean age was 60.5 (SD = 9.0). Median time to diagnosis was 69 days (IQR = 32–127 days), with a median latency of 30 days (IQR = 12–61 days) from symptom onset to first presentation and 19.5 days (IQR = 4–46 days) from the first presentation to diagnosis. Most patients visited at least 2 providers (n = 52, 74%) before diagnosis. Evaluation by 3 or more providers prior to diagnosis was associated with significant delays in diagnosis of nearly a year (357.7 days, p < 0.001) and being treated or prescribed analgesia prior to diagnosis was significantly associated with delays in diagnosis (p = 0.004) on univariate regression analysis.ConclusionsDelays in care related to evaluations by multiple providers and misdiagnosis prolonged time to diagnosis in HPV(−)OPSCC. Improved patient and provider education is necessary to expedite the diagnosis of HPV(−)OPSCC.Level of Evidence4 Laryngoscope, 133:1394–1401, 2023
Urticaria and/or angioedema secondary to mRNA COVID ‐19 vaccines: Updates from a United States case registry
Anvari, Sara , Jaggers, Jordan, Gonzalez‐Estrada, Alexei , Chong, Hey , Meerbeke, Sara W. Van, Petrov, Andrej A. , Khan, David A. , Freeman, Esther E. , Banerji, Aleena , Blumenthal, Kimberly G. , Gonzalez-Estrada, Alexei , Blumenthal, Kimberly G , Samarakoon, Upeka , Fu, Xiaoqing

Mayo Clinic

Allergy | July 17, 2022 | Volume: 78 | Issue: 1 | Pages: 283-286

10.1111/all.15447 | PMID 35842747 Get It